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Mr Michael Dixon [1] examined whether neoadjuvant endo-
crine or chemotherapy might interfere with the assessment of
prognostic factors that are normally used to predict
prognosis in patients with breast cancer. The major compo-
nents for prognosis include tumour size, node status, tumour
grade, oestrogen receptor (ER) status, and HER2/neu status.
Newer prognostic factors include changes in tumour
parameters before and after neoadjuvant therapy. The major
parameters are Ki67 index, change in gene expression during
treatment and changing tumour size during treatment.
Mr Dixon concluded that one would be able to measure
tumour size accurately at the time of diagnosis with magnetic
resonance imaging, ultrasound, or clinical measurement. In
the discussion period the question was raised whether these
three parameters can, in fact, accurately predict overall
tumour size. With accurate ultrasound and fine needle
aspiration (FNA), it might be possible to detect nodal status
at the time of neoadjuvant therapy. However, sentinel node
techniques have not been used in this setting, and some
concern about the use of ultrasound and FNA was raised
during the discussion. A key aspect of the presentation was
that other parameters might provide additional predictive
factors. For example, reduction in tumour size, Ki67, or other
parameters during neoadjuvant therapy might provide
additional information about ultimate prognosis.
Dr Craig Allred [2] reviewed the evidence for and against the
possibility that all breast cancers arise from ER-positive
precursors. This has been a subject of major controversy
regarding the stem cells or transitional cells that give rise to
breast cancer. After his review, Dr Allred concluded that
some ER-negative breast cancers probably arise from ER-
positive precursors, and that some ER-positive tumours arise
from ER-negative cells. He indicated that a key practical issue
is the need to develop means to convert ER-negative to ER-
positive tumours to enhance responsiveness to hormonal
therapy. During his presentation, Dr Allred provided striking
histological evidence that a great deal of heterogeneity exists
within individual tumours. Within one tumour, there may be
coexisting portions that are grade I, II, or III and areas that are
ER-positive and other areas that are ER-negative. He
indicated that this phenomenon must be taken into account
when interpreting cDNA array data or other molecular
techniques that utilize the entire tumour for analysis.
Dr Carol Fabian [3] discussed use of surrogate end-point
biomarkers to assess prognosis and the risk for developing
breast cancer in patients. She focused her remarks on the
ability of random, peri-areolar fine needle aspirations to detect
intraepithelial neoplasia or atypical ductal hyperplasia. In her
experience, these techniques are associated with minimal
discomfort and feasible in large numbers of women. She
reviewed her experience with arzoxifene, a third-generation
selective ER modulator, in comparison with placebo. There
was no change in cytomorphology index score, but there was
a significant favourable modulation of mammographic breast
density, breast tissue ER expression and serum insulin-like
growth factor (IGF)-1/IGF binding protein-3 ratio. These
changes were more marked in premenopausal than in
postmenopausal women. Dr Fabian then commented that the
major source of oestrogen in postmenopausal women is
direct in situ production in the breast. Accordingly, it might be
possible to give an aromatase inhibitor plus hormone
replacement therapy (HRT). A study is currently examining
this possibility.
Professor William Miller [4] then evaluated whether changes
in genes regulated by oestrogen in breast cancer cells might
provide predictive information regarding responsiveness to
aromatase inhibitors. He reviewed the gene array results in
five separate studies with cell lines and with his own data in
patients receiving neoadjuvant therapy. It would appear that
there are major differences among studies with respect to the
genes identified to be oestrogen responsive at the present
time. These genes do not predict breast cancer responsive-
ness. He noted that the nine most commonly quoted
oestrogen-regulated genes in MCF7 cells were NRIP1,
STC2, CCND1, MYB and TFF1 (which are downregulated),
and  ARK4,  IGFBP4,  SCL7A5 and  TPD52-1 (which are
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relatively unaffected by treatments in both responders and
nonresponders). He concluded that oestrogen-regulated
genes are molecular markers of oestrogen sensitivity (but not
dependence). He further concluded that expression profiles
and molecular responses to endocrine therapy in clinically
resistant tumours may be similar to those in clinical
responders, and therefore that most oestrogen-regulated
genes are unlikely to be robust markers of clinical response
and therapy.
Dr Richard Santen [5] then reviewed an hypothesis that he
called the ‘oestrogen paradox’. This concept suggests that
short-term oestrogen (without concomitant progestin)
reduces the risk for breast cancer and long-term use
increases the risk. He reviewed the epidemiological data from
the Women’s Health Initiative study, the Nurses Health Study,
the Lyytenen study and others that indicate that short-term
oestrogen is associated with a trend toward a decrease in
breast cancer risk. Long-term use of oestrogen in the Nurses
Health Study and others was associated with an increased
risk for breast cancer.
The hypothesis to explain this oestrogen paradox is that
oestrogen causes apoptosis in cells adapting to long-term
oestrogen-deprivation therapy. On the other hand, long-term
exposure to oestrogen causes an increased number of
mutations both through ER-mediated increases in cell
proliferation and through direct genotoxic effects of
oestrogen. Underlying this thinking is that there is a reservoir
of undiagnosed tumours (approximately 6%) in women
starting HRT, and that these tumours can respond to
oestrogen in the short term with apoptosis and a reduced
detection rate over the next 5 to 9 years. Dr Santen noted
that direct demonstration of oestrogen-induced apoptosis in
occult breast cancers in women will be critical.
Finally, Dr Craig Jordan [6] reviewed data regarding oestro-
gens in patients with breast cancer. He initially presented
information regarding tamoxifen and use of oestrogens as
breast cancer therapy. The major emphasis was on the fact
that substantial data exist to show that high-dose oestrogens
cause tumour regression in patients with heavily treated
hormone-dependent breast cancer. His group has conducted
a number of studies in vitro and  in vivo to show that
oestrogens induce apoptosis. He indicated that during the
process of development of drug resistance, the component of
oestrogen-induced apoptosis becomes evident. Recognition
of the new biology of oestrogen action that causes apoptosis
in tumours developing hormone resistance now opens up an
unanticipated door of opportunity to exploit the findings in
patients. He proposes that periodic ‘oestradiol purge’ will
deplete tumours of cells that are resistant to tamoxifen or
aromatase inhibitors. His group has now received a large
Department of Defense Centers of Excellence grant to study
this hypothesis in patients with breast cancer.
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